KalVista Pharmaceuticals (KALV) Revenue & Revenue Breakdown
KalVista Pharmaceuticals Revenue Highlights
00
KalVista Pharmaceuticals Revenue by Period
KalVista Pharmaceuticals Revenue by Year
| Date | Revenue | Change |
|---|---|---|
| 2024-04-30 | - | 100.00% |
| 2023-04-30 | - | 100.00% |
| 2022-04-30 | - | -100.00% |
| 2021-04-30 | $12.69M | - |
| 2020-04-30 | $12.69M | -21.31% |
| 2019-04-30 | $16.13M | 92.13% |
| 2018-04-30 | $8.39M | 458.11% |
| 2017-04-30 | $1.50M | -29.49% |
| 2016-04-30 | $2.13M | 18.24% |
| 2015-04-30 | $1.80M | 334.70% |
| 2013-12-31 | $415.00K | -73.02% |
| 2012-12-31 | $1.54M | - |
KalVista Pharmaceuticals generated - in revenue during NA 2024, up 100.00% compared to the previous quarter, and up 0.00% compared to the same period a year ago.
KalVista Pharmaceuticals Revenue by Quarter
| Date | Revenue | Change |
|---|---|---|
| 2024-07-31 | - | -100.00% |
| 2024-04-30 | $1.21M | 100.00% |
| 2024-01-31 | - | 100.00% |
| 2023-10-31 | - | 100.00% |
| 2023-07-31 | - | 100.00% |
| 2023-04-30 | - | 100.00% |
| 2023-01-31 | - | 100.00% |
| 2022-10-31 | - | 100.00% |
| 2022-07-31 | - | 100.00% |
| 2022-04-30 | - | 100.00% |
| 2022-01-31 | - | 100.00% |
| 2021-10-31 | - | 100.00% |
| 2021-07-31 | - | -100.00% |
| 2021-04-30 | $12.69M | 100.00% |
| 2021-01-31 | - | 100.00% |
| 2020-10-31 | - | 100.00% |
| 2020-07-31 | - | -100.00% |
| 2020-04-30 | $3.82M | 142.49% |
| 2020-01-31 | $1.58M | -59.77% |
| 2019-10-31 | $3.92M | 16.36% |
| 2019-07-31 | $3.37M | 15.14% |
| 2019-04-30 | $2.93M | -24.78% |
| 2019-01-31 | $3.89M | -30.44% |
| 2018-10-31 | $5.59M | 50.40% |
| 2018-07-31 | $3.72M | -23.18% |
| 2018-04-30 | $4.84M | 107.64% |
| 2018-01-31 | $2.33M | 106.83% |
| 2017-10-31 | $1.13M | 1073.96% |
| 2017-07-31 | $96.00K | -15.79% |
| 2017-04-30 | $114.00K | -54.03% |
| 2017-01-31 | $248.00K | 100.00% |
| 2016-09-30 | - | -100.00% |
| 2016-06-30 | $7.00K | - |
| 2016-03-31 | $7.00K | -12.50% |
| 2015-12-31 | $8.00K | 14.29% |
| 2015-09-30 | $7.00K | - |
| 2015-06-30 | $7.00K | -12.50% |
| 2014-12-31 | $8.00K | -20.00% |
| 2014-09-30 | $10.00K | 100.00% |
| 2014-06-30 | $5.00K | -16.67% |
| 2014-03-31 | $6.00K | -98.49% |
| 2013-12-31 | $398.00K | - |
KalVista Pharmaceuticals generated - in revenue during Q1 2025, up -100.00% compared to the previous quarter, and up NaN% compared to the same period a year ago.
KalVista Pharmaceuticals Peer Comparison by Revenue
| Ticker | Company | Last Year Revenue | Last Quarter Revenue |
|---|---|---|---|
| IMCR | Immunocore | $249.43M | $75.40M |
| MIRM | Mirum Pharmaceuticals | $186.37M | $77.88M |
| MRSN | Mersana Therapeutics | $36.85M | $12.60M |
| CYTK | Cytokinetics | $7.53M | $463.00K |
| KRON | Kronos Bio | $6.29M | $2.37M |
| CRNX | Crinetics Pharmaceuticals | $4.01M | - |
| LYRA | Lyra Therapeutics | $1.56M | $195.00K |
| KRTX | Karuna Therapeutics | $654.00K | - |
| VRDN | Viridian Therapeutics | $314.00K | $86.00K |
| CGEM | Cullinan Oncology | - | - |
| COGT | Cogent Biosciences | - | - |
| GOSS | Gossamer Bio | - | $9.48M |
| DICE | DICE Therapeutics | - | - |
| DYN | Dyne Therapeutics | - | - |
| REPL | Replimune Group | - | - |
| KURA | Kura Oncology | - | - |
| SNDX | Syndax Pharmaceuticals | - | $12.50M |
| LRMR | Larimar Therapeutics | - | - |
| NVCT | Nuvectis Pharma | - | - |
| KALV | KalVista Pharmaceuticals | - | - |
| EWTX | Edgewise Therapeutics | - | - |